GENEXI

Ended (crowdsale)
Genexi accelerates the transition of cutting-edge biotech projects from research to the market.

Whitepaper Project Demo

4.1
Rating

Sale Ends in

Ended

Pre-Sale: 1 May 2018 - 31 May 2018
Main Sale: 1 Jun 2018 - 10 Sep 2018

Token Price

1 GEN = 0.01 USD

Symbol
GEN
Platform
Ethereum
Type
ERC20
Decimals
Total Supply
12,000,000,000 GEN
For Sale
8,400,000,000 GEN
Softcap
20,000,000 USD
Hardcap
70,000,000 USD
Min. Investment
N/A
Max. Investment
N/A
Whitelist
NO
KYC
YES
Accepts
ETH, BTC, BCH, LTC, Other
Incorporated in
Singapore
Restricted in
USA
Tokens Distribution
70% Public Distribution
10% Long-term Foundation Reserve
15% Founders & Team
5% Advisors & Early Contributors
Funds Allocation
60% Community Grants, Partnerships & Software Development
20% Marketing and Business Development
10% Operational Expenses
5% Legal Expenses
5% Misc and Unexpected
GENEXI Platform

GENEXI Platform is an innovative solution provided by the GENEXI Dev Team for the e-commerce market in order to support GENEXI Ecosystem development.

The platform unites biotech producers, distributors, retailers and end-consumers in one blockchain solution based globally operating ecosystem. Utilizing the powers of the platform, a biotech producer can focus priorly on development and production, significantly cutting the costs of marketing and consulting, and attract multiple distributors without having to establish a wide range of products first.

At the same time, distributors and retailers will also gain advantages by obtaining access to a growing number of cutting-edge biotech-product within the GENEXI QA Control System.

The Product Authenticity Verification System is designed to ensure full track of the supply chain, authenticity verification and complete production data and report.

The production and supply chains become fully transparent with the use of the blockchain technologies; the information added to the ledger is available for all the ecosystem participants. The statistical data obtained via shipment tracking will contribute a lot to GENEXI market development and could constitute yet an additional source of income applied to the e-commerce processes.

All the transactions within the ecosystem will be processed via smart-contracts, thus preventing the necessity to apply to middle-men and third-party services and vastly reducing the risk of fraud, all resulting in a significantly lower end price. In case of dispute, the parties can appeal to an Arbitrator for resolution.

Therefore, GENEXI Platform will provide an end-user with access to unique state-of-of-the-art sensations of the biotech industry, fully protected with distributed ledger technologies in production and supply chains.

GENEXI targets to utilize the advantages of blockchain to mitigate fraudulent activities in the biotech industry

  • Blockchain provides transparency in the clinical research processes
  • Blockchain ensures that the data supplied by the clinical research process is credible and immutable
  • Blockchain smart-contracts allow for automation of the process and enable decentralized control for investors

Blockchain technology stops the entry of fake drugs into the supply chain, first and foremost between the manufacturer and the consumer.

The technology uses a highly flexible transparent system in order to assign each manufactured product an asset. These assets are added to the blockchain and assigned a unique identification number, commonly referred to as hash. Then the technology verifies the hashes to find out whether the product is counterfeit or legitimate.

Every product can be verified using this technology. Anyone can get access to the blockchain and conduct their own product verifications. Moreover, no duplicate items can be created. Blockchain creates a visible supply chain where suppliers, vendors, distributors and partners are close-knit.

All transactions are recorded; location, quality, price, and other data is visible to all concerned parties.

Only trusted parties are allowed to write on the blockchain system. Manufacturers and consumers can scan the barcode and view the history.

The platform also reports whenever a counterfeit drug is found. Altogether the solutions combined make the GENEXI platform an ideal business decision.

Team Members
Aleksei Zheliaskov
Founder, CEO
Roman Gilvanov
Managing Director
Sergey Tiurin
Head of Medical Research
Alexey Nosikov
Head of Operations
Andrew Marcus
Head of Strategy
Bogdan Stepanov
Head of Business Development
Anton Sklovets
Head of Research
Daria Goriychuk
Head of HR
Aleksei Khokhlov
CTO
Alexander Novoselov
Biotech Analyst
Maxim Khotimchenko
Biotech Expert
Anton Nizhenkov
Investment Analyst
Dennis Sarkar
Ecosystem Developer
Jacques Miabouna
Strategy Consultant
Vladimir Stark
Head of Marketing
Anastasia Verbitskaya
SMM
Denis Baldakov
Community Manager
Artem Targosh
Community Manager
Stepan Razenkov
Business Analyst
Anna Rafaelli
Chief Editor
Anna Fursova
PR Manager
Margarita Ilina
PR Manager
Egor Stepanov
Head of IT
Alexander Abarevich
Technical Support Lead
Katrina Arden
Escrow
Advisors
Roel Wolfert
Advisor
Oliver Bussmann
Advisor
Malcolm Tan
Advisor
Anti Danilevski
Advisor
Richard O'Rourke
Advisor
Manuel Rimarachin
Advisor
Partners
qoin
gravitis holdings
b2bx
  • From 2014
    Scientific and Medical Research
  • Q1 2017
    GENEXI Establishment
  • Q3 2017
    Ecosystem and Platform Development

    Foundation Establishment
  • Q1 2018
    High Level Ecosystem Design
  • Q2 2018
    Low Level Design

    Launch
  • 04-08.2018
    Fundraising
  • Q3 2018
    Ecosystem Alpha Version Testing
  • Q4 2018
    Smart-Contract Development and Testing

    Grant Application Program Launch
  • H1 2019
    Ecosystem Complete Version Launch
  • H2 2019
    Official Public GENEXI Foundation Report
  • 2019
    Android & IOS Platform Applications
  • 2020 and later
    Further Platform and Ecosystem development and scaling
Bonus Details
Pre-Sale
20%
01.06 – 14.06
17%
15.06 – 05.07
9%
06.07 – 26.07
5%
27.07 – 10.09
2%
Sale Commission (Aff/Ref)
%
Bounty Details
Total Budget =
Campaign Share

Product

Data
Result
Product Differentiation
90%
Blockchain Utilization
100%
Whitepaper Presentation
80%
Roadmap
75%
MVP/Prototype
100%
89%

Business

Data
Result
Valuation
90%
Market Potential
100%
Competition
90%
Legal
100%
95%

Token

Data
Result
Token Usage
80%
Smart Contract
0%
Fundraising Goals
100%
Token Allocation
90%
Funds Usage
95%
73%

Team

Data
Result
Background of Management Team
90%
Team LinkedIn Profiles
71%
Team KYC
100%
Quality of Advisors
85%
Quality of Partners
80%
85%

Community

Data
Result
Size of Community
85%
Social Activity
80%
Marketing
30%
Support
100%
74%
0
Rating
Investor (0 votes) {{ reviewsOverall }} / 5
What investor say... Leave your rating
Order by:

Be the first to leave a review.

User Avatar User Avatar
Verified
{{{ review.rating_title }}}
{{{review.rating_comment | nl2br}}}

Show more
{{ pageNumber+1 }}
Leave your rating